ES2134778T3 - Bistriazenos como agentes quimioterapeuticos. - Google Patents

Bistriazenos como agentes quimioterapeuticos.

Info

Publication number
ES2134778T3
ES2134778T3 ES91910672T ES91910672T ES2134778T3 ES 2134778 T3 ES2134778 T3 ES 2134778T3 ES 91910672 T ES91910672 T ES 91910672T ES 91910672 T ES91910672 T ES 91910672T ES 2134778 T3 ES2134778 T3 ES 2134778T3
Authority
ES
Spain
Prior art keywords
compounds
bistriazene
cancer
bistriazenes
chemotherapeutical agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91910672T
Other languages
English (en)
Inventor
Christopher J Michejda
Jeffrey J Blumenstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Commerce
Original Assignee
United States Department of Commerce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Commerce filed Critical United States Department of Commerce
Application granted granted Critical
Publication of ES2134778T3 publication Critical patent/ES2134778T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/22—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond containing chains of three or more nitrogen atoms with one or more nitrogen-to-nitrogen double bonds
    • C07C245/24—Chains of only three nitrogen atoms, e.g. diazoamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCION SE DIRIGE A COMPUESTOS DE BISTRIACENO, A LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN CANTIDADES EFICACES CONTRA EL CANCER DE ESTOS PRODUCTOS, UN METODO PARA EL TRATAMIENTO DEL CANCER QUE COMPRENDE LA ADMINISTRACION A SUJETOS AFECTADOS DE UNA CANTIDAD EFICAZ CONTRA EL CANCER DE UN COMPUESTO DE BISTRIACENO Y EL EMPLEO DE LOS COMPUESTOS DE BISTRIACENO COMO REACTIVOS DE ENLACES CRUZADOS APLICABLES A LA SINTESIS Y LA MANIPULACION DE MACROMOLECULAS POLIMERICAS.
ES91910672T 1990-05-24 1991-05-22 Bistriazenos como agentes quimioterapeuticos. Expired - Lifetime ES2134778T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52791590A 1990-05-24 1990-05-24

Publications (1)

Publication Number Publication Date
ES2134778T3 true ES2134778T3 (es) 1999-10-16

Family

ID=24103474

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91910672T Expired - Lifetime ES2134778T3 (es) 1990-05-24 1991-05-22 Bistriazenos como agentes quimioterapeuticos.

Country Status (10)

Country Link
US (2) US5672593A (es)
EP (1) EP0531419B1 (es)
JP (1) JPH05506452A (es)
AT (1) ATE182468T1 (es)
AU (1) AU642273B2 (es)
CA (1) CA2083148C (es)
DE (1) DE69131481T2 (es)
DK (1) DK0531419T3 (es)
ES (1) ES2134778T3 (es)
WO (1) WO1991017753A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5808038A (en) * 1990-05-24 1998-09-15 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bistriazenes as chemotherapeutic agents
DE69230622T2 (de) * 1991-10-31 2000-07-20 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Bistriazene als chemotherapeutische wirkstoffe
US5548070A (en) * 1993-07-22 1996-08-20 Wacker-Chemie Gmbh Organosilicon compounds having triazene groups
DE19508076C2 (de) * 1995-03-08 1998-04-30 Csb Syst Software Entwicklung Schaltungsanordnung zur Integration eines Sprachsystems in EDV-Systeme und Telefonanlagen, die an das öffentliche Telefonnetz angeschlossen sind
ZA973642B (en) * 1996-04-26 1997-11-25 Merck & Co Inc DNA vaccine formulations.
US6875907B2 (en) 2000-09-13 2005-04-05 Pioneer Hi-Bred International, Inc. Antimicrobial peptides and methods of use
WO2003027243A2 (en) 2001-09-27 2003-04-03 Pioneer Hi-Bred International, Inc. Phytate polynucleotides and methods of use
US7358419B2 (en) 2002-04-08 2008-04-15 Pioneer Hi-Bred International, Inc. Enhanced silk exsertion under stress
US7987056B2 (en) 2004-09-20 2011-07-26 The Regents Of The University Of Colorado, A Body Corporate Mixed-library parallel gene mapping quantitative micro-array technique for genome-wide identification of trait conferring genes
KR20160116056A (ko) 2008-08-14 2016-10-06 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 항-ｉｌ-12/ｉｌ-23 항체
EP2557075A1 (de) 2011-08-09 2013-02-13 Trin Therapeutics GmbH Neue Triazenverbindungen zur Behandlung von Krebs
AR088515A1 (es) 2011-10-25 2014-06-18 Pioneer Hi Bred Int Metodos para alterar la composicion de la pared celular vegetal para obtener produccion de biocombustible y digestibilidad de silaje mejoradas
WO2020121304A1 (en) * 2018-12-10 2020-06-18 Ariel Scientific Innovations Ltd. Therapeutic conjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3138521A (en) * 1960-10-04 1964-06-23 Gen Aniline & Film Corp Fungicidal method
CH482789A (de) * 1967-03-16 1969-12-15 Ciba Geigy Verfahren zur Herstellung neuer Disazofarbstoffpigmente
DE1793115A1 (de) * 1968-08-03 1972-02-03 Bayer Ag Neue Triazenderivate
DE3426644A1 (de) * 1984-07-19 1986-02-06 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts, 6900 Heidelberg N,n-bis((1-aryl-3-methyltriazen-3-yl) methyl)ether
US4923970A (en) * 1988-03-28 1990-05-08 Bionetics Research, Inc. Substituted 1-(2-chloroethyl)-3-acyl-3-alkyltriazenes

Also Published As

Publication number Publication date
EP0531419A1 (en) 1993-03-17
EP0531419A4 (en) 1994-04-06
EP0531419B1 (en) 1999-07-28
US5672593A (en) 1997-09-30
JPH05506452A (ja) 1993-09-22
DE69131481T2 (de) 1999-11-25
CA2083148A1 (en) 1991-11-25
WO1991017753A1 (en) 1991-11-28
ATE182468T1 (de) 1999-08-15
US5731301A (en) 1998-03-24
AU8089791A (en) 1991-12-10
DK0531419T3 (da) 1999-11-29
CA2083148C (en) 2002-01-01
DE69131481D1 (de) 1999-09-02
AU642273B2 (en) 1993-10-14

Similar Documents

Publication Publication Date Title
TR200100918T2 (tr) Aril ve heteroaril sübstitüentli üreler kullanılarak RAF kinazın inhibe edilmesi
IS4073A (is) Nýtt fjölvirknislyf gegn aukningu mótstöðu
DK0490077T3 (da) Antisense-oligonukleotider til behandling af cancer
FI972086A7 (fi) Parannetun monilääkeresistenssiaktiivisuuden omaavat uudet aminohappoj ohdokset
DK65293D0 (da) Fremgangsmaade til administrering af taxol
ES2169127T3 (es) Nuevos carbamatos y ureas como modificadores de la resistencia multi-farmaco.
ES2063073T3 (es) Derivados de arilmetilenilo conocidos y nuevos seleccionados de tiazolidinonas, imidazolidinonas y oxazolidinonas utiles como agentes antialergicos y agentes antiinflamatorios.
ES2167377T3 (es) Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos.
YU13396A (sh) N-(3-benzofuranil) urea derivati, postupci za njihovo dobijanje, kompozicije koje ih sadrže i njihova upotreba u lekovima
ATE218142T1 (de) Nitratester von corticoid verbindungen und die therapeutische verwendungen davon
BG103219A (bg) Бензамидинови производни и използването им като лекарствени средства с ltb4-антагонистично действие
LU88317I2 (fr) Chlorhydrate d'esmolol (Brevibloc)
DK0531419T3 (da) Bistriazener som kemoterapeutiske midler
DE68902301D1 (de) Diarylverbindungen als antiatherosklerotische mittel.
TR199700711T1 (xx) Ciltten ge�erek v�cuda giren form�lasyon.
IL64956A0 (en) Tetrahydronaphthalene and indane derivatives,their manufacture and pharmaceutical compositions containing them
ATE43967T1 (de) Antitumorale arzneimittel und verbindungen fuer behandlung von tumoren unter anwendung von (alpha, omega-bis(disubstituierte phosphino) kohlenwasserstoff> digold (i), digold (iii), disilber (i) und dikupfer (i)-derivaten.
ES502654A0 (es) Un procedimiento para la preparacion de nuevos derivados de 2-propanol
BR9106272A (pt) Composicoes farmaceuticas contendo ipriflavona,processo para sua preparacao e uso terapeutico relativo
ES2141114T3 (es) Bistriazenos utilizados como agentes quimioterapeuticos.
DE69814691D1 (de) Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten
ATE233745T1 (de) Arzneistoffe
ATE22282T1 (de) Pentacycloundecan derivate, verfahren zu ihrer herstellung, und diese enthaltende pharmazeutische zusammensetzungen.
KR890017363A (ko) 스트로빌루린 유도체, 이들의 제법 및 용도
BR0211762A (pt) Certos policetìdeos substituìdos, composições farmacêuticas contendo os mesmos e seu uso no tratamento de tumores

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 531419

Country of ref document: ES